Lidocaine, Dexmedetomidine, Esmolol and Magnesium Effect on Optic Nerve Sheath Diameter After Laryngoscopy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorHaseki Training and Research Hospital

About this trial

This clinical trial aims to compare the effects of lidocaine, dexmedetomidine, esmolol, and magnesium on optic nerve sheath diameter and hemodynamic response to laryngoscopy.

The participants will be patients determined to need intubation and general anesthesia for any elective surgery. Each participant will receive either lidocaine, dexmedetomidine, esmolol, magnesium, or none before anesthesia induction, according to randomization. The investigator will measure the optic nerve sheath diameter by ultrasonography before and after intubation. Researchers will compare the difference between optic nerve sheath diameter, systolic blood pressure, and heart rate before and after laryngoscopy and search for the most stable group. The trial aims to determine a general anesthesia induction protocol for patients sensitive to intracranial pressure changes reflected as optic nerve sheath diameter for easy monitoring.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients aged 18 to 80 years who will receive endotracheal intubation for general anesthesia and have an American Society of Anesthesiologists (ASA) Physical Status classification of I to III.

Disqualifiers

Patients allergic to dexmedetomidine, esmolol, lidocaine, and magnesium; patients with uncontrolled hypertension or advanced heart failure with EF below 35%; patients with cardiac arrhythmia, especially Type 2 and 3 blocks, supraventricular arrhythmias. Patients with renal failure (GFR below 30) or severe liver failure; patients with known acute or previous intracranial pathology and known diagnosis of epilepsy, predefined difficult airway examination. Patients who required more than one attempt at intubation or total laryngoscopy took more than 20 seconds.

Trial design

Design model

Parallel

Treatments tested in this trial

  • optic nerve ultrasonography

    Diagnostic test

    The primary investigator measured ONSD at times: first after anesthesia induction before laryngoscopy, second just after laryngoscopy, third five minutes after, and fourth ten minutes after intubation by ultrasound guidance with a high-frequency linear probe at T2 ophthalmic preset.

Treatment groups

100 Participants
are divided into 5 treatment groups
Group A: ControlPlacebo comparator 1 intervention
Group B: LidocaineExperimental treatment 1 intervention
Group C: magnesiumExperimental treatment 1 intervention
Group D: dexmedetomidineExperimental treatment 1 intervention
Group E: EsmololExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

optic nerve sheath diameter

optic nerve sheath ultrasonography will be used to measure optic nerve sheath diameter with a high-frequency linear probe at T2 ophthalmic preset at a distance of 3 mm from the posterior globe

Time frame
throughout the anesthesia

Secondary outcomes

1

mean arterial pressure

mean arterial pressure will be recorded at times of optic nerve sheath measurements

Time frame
throughout the anesthesia
2

heart rate

heart rate will be recorded at times of optic nerve sheath measurements

Time frame
throughout the anesthesia

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.